Registered as a biopharmaceutical company, MabVax Therapeutics Holdings, Inc. continues to develop, discover and commercialize human monoclonal antibodies that are used to treat various forms of cancer. The business has strong ties with Memorial Sloan-Kettering Cancer Center (MSKCC).
The human monoclonal antibody products that are being developed by the company are discovered from patients who have received vaccination for certain cancers from the Memorial Sloan-Kettering Cancer Center (MSKCC). These patients have generated a protective immune response to certain cancers. The antibodies that are being developed by the company have promising results to treat colon cancer, stomach, pancreatic, gastrointestinal, breast, small lung cancer cells and as well as ovarian cancer.
Their lead antibody candidate, the 5B1, is also being used as a diagnostic imaging product, to detect the presence and proliferation of cancer cells. MabVax is located in San Diego, California and is traded publicly on the Over-the-Counter Markets, using the symbol MBVX.
No comments:
Post a Comment